» Articles » PMID: 33836476

Epilepsy Outcome at Four Years in a Randomized Clinical Trial Comparing Oral Prednisolone and Intramuscular ACTH in West Syndrome

Overview
Journal Pediatr Neurol
Specialties Neurology
Pediatrics
Date 2021 Apr 9
PMID 33836476
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This article explores the role of initial treatment on control of spasms and other epilepsies at four years in children previously treated for West syndrome.

Methods: The Sri Lanka Infantile Spasm Study is a prospective clinical trial evaluating response to intra-muscular adrenocorticotropic hormone (ACTH) versus oral prednisolone. A previous report documented response through age 12 months. This article provides four-year follow-up data.

Results: At age four years, 65 of the original 97 were available for follow-up; another 13 had died, and 19 moved and could not be contacted. Of the 65 children, 37 (57%) continued to have seizures and 28 were seizure free. In the 37 children with ongoing epilepsy, 32.4% continued to have spasms, either alone or in combination with other seizure types. The epilepsy types seen in these children were focal epilepsy (59.4%), mixed focal and generalized epilepsy (24%), generalized epilepsy only (10.8%), and uncertain (5%). The majority of those still having epilepsy (66.7%) were controlled on medication. There was no significant difference in the rate of epilepsy or spasms or their control by medication between those treated with ACTH or oral prednisolone. Spasm control at day 14 did not influence the four-year spasm or epilepsy outcome.

Conclusions: A majority of children diagnosed with West syndrome continued to have seizures at age four years, although most were controlled on antiseizure medication. The long-term risk of developing epilepsy or its control was the same, regardless of whether ACTH or prednisolone was initially used as treatment.

Citing Articles

Efficacy and Safety of Pulse Intravenous Methylprednisolone in Pediatric Epileptic Encephalopathies: Timing and Networks Consideration.

Russo A, Mazzone S, Landolina L, Colucci R, Baccari F, Fetta A J Clin Med. 2024; 13(9).

PMID: 38731025 PMC: 11084200. DOI: 10.3390/jcm13092497.


Brazilian experts' consensus on the treatment of infantile epileptic spasm syndrome in infants.

Sampaio L, Maria de Miranda Henriques-Souza A, da Silveira M, Seguti L, Schmitz Ferreira Santos M, Montenegro M Arq Neuropsiquiatr. 2023; 81(9):844-856.

PMID: 37793406 PMC: 10550353. DOI: 10.1055/s-0043-1772835.


The landscape of infantile epileptic spasms syndrome in South Asia: peculiarities, challenges, and way forward.

Sahu J, Madaan P, Prakash K Lancet Reg Health Southeast Asia. 2023; 12:100170.

PMID: 37384052 PMC: 10306027. DOI: 10.1016/j.lansea.2023.100170.


Corticosteroids in childhood epilepsies: A systematic review.

Becker L, Kaindl A Front Neurol. 2023; 14:1142253.

PMID: 36970534 PMC: 10036579. DOI: 10.3389/fneur.2023.1142253.


Clinical characteristics of children with infantile epileptic spasms syndrome from a tertiary-care hospital in Dhaka, Bangladesh.

Briscoe Abath C, Chandra Saha N, Hoque S, Islam A, Chowdhury Y, Ara Begum M Heliyon. 2023; 9(3):e14323.

PMID: 36950644 PMC: 10025103. DOI: 10.1016/j.heliyon.2023.e14323.